DOCSLIB.ORG

National Code Item Name 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NATIONAL CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 800,000 02-01-00002 Digitoxin 100mcg Tablet 800,000 02-01-00003 Digoxin 125 mcg Tablet 800,000 02-01-00004 Digoxin 250 mcg Tablet 15,000,000 02-01-00005 Digoxin 50mcg /ml PG Elixir 800,000 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 800,000 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 800,000 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 50,000,000 02-01-00009 Bumetanide 1 mg Tablet 800,000 02-01-00010 Chlorthalidone 50mg Tablet 2,867,000 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 800,000 02-01-00012 Frusemide 20mg/2ml inj Ampoule 6,625,000 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 800,000 02-01-00014 Frusemide 40mg Tablet 20,000,000 02-01-00015 Frusemide 500mg Scored Tablet 800,000 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 800,000 02-01-00017 Frusemide 4mg/ml Oral Solution 800,000 02-01-00018 Frusemide 8mg/ml oral Solution 800,000 02-01-00019 Hydrochlorothiazide 25mg Tablet 800,000 02-01-00020 Hydrochlorothiazide 50mg Tablet 950,000 02-01-00021 Indapamide 2.5mg Tablet 800,000 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 800,000 02-01-00023 Spironolactone 25mg Tablet 7,902,000 02-01-00024 Spironolactone 100mg Tablet 11,451,000 02-01-00025 Xipamide 20mg Tablet 800,000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 800,000 02-01-00027 Acebutolol 200mg Tablet 800,000 02-01-00028 Atenolol 100mg Tablet 120,000,000 02-01-00029 Atenolol 50mg Tablet or (scored tab) 20,000,000 02-01-00030 Atenolol 25mg Tablet 1,483,000 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 800,000 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 800,000 02-01-00033 Carvedilol 6.25mg Tablet 800,000 02-01-00034 Carvedilol 12.5mg Tablet 800,000 02-01-00035 Carvedilol 25mg Tablet 800,000 02-01-00036 Esmolol Hcl 10mg/ml I.V. infusion (10ml) Vial 800,000 02-01-00037 Labetalol inj. 5mg/ml (20ml) Ampoule 800,000 02-01-00038 Labetalol 200mg Tablet 800,000 02-01-00039 Labetalol 400mg Tablet 800,000 02-01-00040 Metoprolol 50mg Tablet 800,000 02-01-00041 Metoprolol 200mg (s/r) Tablet 1,599,000 02-01-00042 Metoprolol tartrate 1mg/1ml I.V. inj (5ml) Ampoule 800,000 02-01-00043 Metoprolol tartrate 100mg (CR ), (Zok ) Tablet 800,000 02-01-00044 Metoprolol tartrate 50mg (CR), (Zok) Tablet 800,000 02-01-00045 Metoprolol succinate 190mg corr.Metoprolol tartrate controlled release tab 200mg (Zok) 800,000 02-01-00046 Nadolol 80mg Tablet 800,000 02-01-00047 Oxprenolol Hcl 40mg Tablet 4,000,000 02-01-00048 Pindolol 5mg Tablet 800,000 02-01-00049 Propranolol Hcl 1mg/ml slow IV inj (1ml) Ampoule 800,000 02-01-00050 Propranolol Hcl 10mg Tablet 20,000,000 02-01-00051 Propranolol Hcl 40mg Tablet (or scored Tablet) 50,000,000 02-01-00052 Propranolol Hcl 80mg (s/r) Capsule 800,000 02-01-00053 Sotalol 40mg Tablet 800,000 02-01-00054 Sotalol 80mg Tablet 800,000 1D ANTI-ARRHYTHMIC DRUGS 02-01-00055 Adenosine inj. 3mg/ml (2ml) Vial 800,000 02-01-00056 Amiodarone Hcl inj 50mg/ml (3ml) Ampoule 800,000 02-01-00057 Amiodarone Hcl 200mg Tablet 9,208,000 02-01-00058 Bretylium tosylate inj 50mg/ml,( 10ml) Ampoule 800,000 02-01-00059 Disopyramide 100mg Capsule 2,829,000 02-01-00060 Disopyramide 150mg (s/r) durules Tablet 800,000 02-01-00061 Disopyramide 250mg retard (s/r) Tablet 800,000 02-01-00062 Disopyramide inj 10mg/ml, (5ml) Ampoule 800,000 02-01-00063 Lidocaine Hcl 20mg/ml slow I.V. infusion ,(50ml Vial) plain 800,000 02-01-00064 Lidocaine Hcl 5% + Dextrose 7.5 % (hyperbaric sol - spinal anesthesia) Injection 800,000 02-01-00065 Lidocaine Hcl 1.5% + Dextrose 7.5 % (hyperbaric sol - spinal anesthesia) Injection 800,000 02-01-00066 Mexiletine Hcl 50mg Capsule 800,000 02-01-00067 Mexiletine Hcl 200mg Capsule 1,550,000 02-01-00068 Mexiletine Hcl 25mg/ml I.V.inj.I.V.infusion (10ml) Ampoule 800,000 02-01-00069 Phenytoin sodium 50mg/ml inj (5ml) Ampoule 800,000 02-01-00070 Practolol 2mg/ml, inj. (5ml) Ampoule 800,000 02-01-00071 Procainamide Hcl 100mg/ml slow I.V.inj. I.V. infusion (10ml) Vial 800,000 02-01-00072 Procainamide Hcl 500mg Tablet 800,000 02-01-00073 Procainamide Hcl 750mg (s/r)Tablet 800,000 02-01-00074 Propafenon Hcl 150mg Tablet 800,000 02-01-00075 Quinidine Bisulfate 250mg equivalent to Quinidine Sulphate 200mg (s/r) Durules Tablet 800,000 02-01-00076 Quinidine Sulphate 200mgTablet 800,000 02-01-00077 Verapamil Hcl inj 2.5mg/ml, (2ml) Ampoule 800,000 02-01-00078 Verapamil Hcl 40mg Tablet 5,588,000 02-01-00079 Verapamil Hcl 80mg Tablet 835,000 02-01-00080 Verapamil Hcl 120mg (s/r) Capsule 800,000 02-01-00081 Verapamil Hcl 120mg (s/r) Tablet 800,000 1E ANTI-HYPERTENSIVE DRUGS 02-01-00082 Alfuzosin Hcl 2.5mg Tablet 952,000 02-01-00083 Alfuzosin Hcl 5mg (s/r)Tablet 964,000 02-01-00084 Alfuzosin Hcl (prolong release) 10mg Tablet 800,000 02-01-00085 Captopril 25mg Tablet 120,000,000 02-01-00086 Captopril 50mg Tablet 60,000,000 02-01-00087 Captopril 12.5mg Tablet 800,000 02-01-00088 Candesartan cilexetil 8mg Scored Tablet 800,000 02-01-00089 Candesartan cilexetil 16mg Tablet 800,000 02-01-00090 Diazoxide 50mg Tablet 800,000 02-01-00091 Doxazosine mesylate equivalent to doxazosin 2mg Scored Tablet 2,506,000 02-01-00092 Doxazosin as mesylate 1mg Tablet 800,000 02-01-00093 Doxazosin as mesylate 4mg Tablet 800,000 02-01-00094 Enalapril maleate 5mg Scored Tablet 1,925,000 02-01-00095 Enalapril maleate 10mg Scored Tablet 2,250,000 02-01-00096 Enalapril maleate 20mg Scored Tablet 1,774,000 02-01-00097 Hydralazine Hcl 20mg I.V. Infusion per Ampoule 800,000 02-01-00098 Hydralazine Hcl 25mg Tablet 837,000 02-01-00099 Hydralazine Hcl 50mg Tablet 800,000 02-01-00100 Irbesartan 150mg Tablet 800,000 02-01-00101 Irbesartan 300mg Tablet 800,000 02-01-00102 Lisinopril as dihydrate 5mg Tablet 3,664,000 02-01-00103 Lisinopril as dihydrate 10mg Tablet 4,145,000 02-01-00104 Lisinopril as dihydrate 20mg Tablet 3,712,000 02-01-00105 Losartan potassium 50mg Tablet 800,000 02-01-00106 Losartan potassium 25mg Tablet 800,000 02-01-00107 Methyldopa 50mg/ml,inj. (5ml) Ampoule 800,000 02-01-00108 Methyldopa 250mgTablet 50,000,000 02-01-00109 Minoxidil 5mgTablet 800,000 02-01-00110 Minoxidil 10mgTablet 800,000 02-01-00111 Perindopril tert- butylamine erbumine 2mg Tablet 800,000 02-01-00112 Perindopril tert- butylamine erbumine 4mg Tablet 800,000 02-01-00113 Phenoxybenzamine Hcl 10mg Capsule 800,000 02-01-00114 Phenoxybenzamine Hcl inj 50mg/ml, (2ml) Ampoule 800,000 02-01-00115 Phentolamine mesylate 10mg/ml, (1ml) Ampoule 800,000 02-01-00116 Prazosin Hcl 0.5mg Tablet 800,000 02-01-00117 Prazosin Hcl 1mg Tablet or Scored Tablet 4,172,000 02-01-00118 Prazosin Hcl 2mg Tablet 800,000 02-01-00119 Prazosin Hcl 5mg Tablet 800,000 02-01-00120 Quinapril Hcl 5mg Tablet 800,000 02-01-00121 Quinapril Hcl 10mg Tablet 800,000 02-01-00122 Quinapril Hcl 20mg Tablet 800,000 02-01-00123 Ramipril 2.5mg Capsule 800,000 02-01-00124 Ramipril 2.5mg Scored Tablet 800,000 02-01-00125 Ramipril 5mg Capsule 800,000 02-01-00126 Ramipril 5mg Scored Tablet 800,000 02-01-00127 Ramipril 10mg Capsule 800,000 02-01-00128 Ramipril 10mg Scored Tablet 800,000 02-01-00129 Ramipril 1.25mg Capsule 800,000 02-01-00130 Reserpine 100mcg Tablet 800,000 02-01-00131 Sodium nitroprussid infusion 30mg Ampoule with solvent 800,000 02-01-00132 Sodium nitroprusside 50mg I.V. infusion Vial with solvent 800,000 02-01-00133 Sodium nitroprusside 50mg I.V. infusion Ampoule with solvent 800,000 02-01-00134 Tolazoline Hcl I.V. Injection 800,000 02-01-00135 Telmisartan 40mg Tablet 8,000,000 02-01-00136 Telmisartan 80mg Tablet 8,000,000 02-01-00137 Valsartan 160mg Capsule 8,000,000 02-01-00138 Valsartan 40mg Capsule 8,000,000 02-01-00139 Valsartan 80mg Capsule 8,000,000 02-01-00140 Valsartan 80mg+hydrochlorthiazide 12.5mg Capsule 8,000,000 02-01-00141 Valsartan 80mg+hydrochlorthiazide 12.5mg Tablet 8,000,000 02-01-00142 Valsartan 160mg+hydrochlorthiazide 12.5mg Capsule 8,000,000 02-01-00143 Valsartan 160mg+hydrochlorthiazide 12.5mg Tablet 8,000,000 1F VASODILATORS 02-01-00144 Amlodipine (as besylate) 2.5mg Tablet 800,000 02-01-00145 Amlodipine (as besylate) 5mg Scored Tablet 1,125,000 02-01-00146 Amlodipine (as besylate) 10mg Scored Tablet 9,071,000 02-01-00147 Cinnarizine 25mg Tablet 15,000,000 02-01-00148 Cinnarizine 75mg Capsule 4,529,000 02-01-00149 Cinnarizine 75mg Tablet 4,529,000 02-01-00150 Diltiazem Hcl 60mg Capsule 7,980,000 02-01-00151 Diltiazem Hcl 60mg Tablet 7,980,000 02-01-00152 Diltiazem Hcl 90mg (s/r) Capsule 3,365,000 02-01-00153 Diltiazem Hcl 90mg (s/r) Tablet 3,365,000 02-01-00154 Diltiazem Hcl 120mg (s/r) Capsule 3,356,000 02-01-00155 Diltiazem Hcl 120mg (s/r) Tablet 3,356,000 02-01-00156 Diltiazem Hcl 180mg (s/r) Capsule 800,000 02-01-00157 Diltiazem Hcl 180mg (s/r) Tablet 800,000 02-01-00158 Diltiazem Hcl 200mg (s/r) Capsule 800,000 02-01-00159 Diltiazem Hcl 200mg (s/r) Tablet 800,000 02-01-00160 Diltiazem Hcl 240mg (s/r) Capsule 800,000 02-01-00161 Diltiazem Hcl 240mg (s/r) Tablet 800,000 02-01-00162 Diltiazem Hcl 300mg (s/r) Capsule 800,000 02-01-00163 Diltiazem Hcl 300mg (s/r)Tablet 800,000 02-01-00164 Diltiazem Hcl 25mg I.V.Infusion Vial 800,000 02-01-00165 Diltiazem Hcl 25mg I.V.Inj Vial 800,000 02-01-00166 Felodipine 5mg Tablet 800,000 02-01-00167 Glyceryl trinitrate 0.5mg Tablet 40,000,000 02-01-00168 Glyceryl trinitrate 5mg/10ml Ampoule 800,000 02-01-00169 Glyceryl trinitrate 5mg Plaster 800,000 02-01-00170 Glyceryl trinitrate 10mg
Recommended publications
  • United States Patent Office

    United States Patent Office

    3,092,548 United States Patent Office Patented June 4, 1963 2 are the various side effects that occur in an appreciable 3,092,548 number of patients, the foremost of which are a blurring METHOD OF TREATING PEPTICULCERS WITH PANTOTHENECACD of vision, drowsiness and a general dry condition mani Albert G. Worton, Columbus, Ohio, assignor to The fested by a retarded salivation, reduction of perspiration Warren-Teed Products Company, Columbus, Ohio, a 5 and diminished urinary output. Other side effects which corporation of Ohio occur in some cases are glaucoma, stimulation of the cen No Drawing. Filed Oct. 27, 1960, Ser. No. 65,256 trol nervous system and in severe cases cardiac and respi 5 Claims. (Ci. 67-55) ratory collapse. These side effects increase to Some de gree with the increase in dosage. Despite the side effects This invention relates to preparation adapted for use O these compounds are fairly selective and highly effective in treating disorders of the gastro-intestinal tract, more in decreasing the volume and acidity of gastric secretion particularly in treating peptic ulcer, both of the duodenal and in reducing gastrointestinal motility. and gastric type, for hyperacidity, hypertropic gastritis, Understandably, the main problem in the past has been splenic flexure syndrome, biliary dyskinesia (postchole to provide a dosage of anticholinergic drug which will cystectomy syndrome) and hiatal hernia or other condi achieve the most beneficial results possible and yet mini tions where anticholinergic effect, either spasmolytic or mize the undesired side effects. One of the objects of antisecretory is indicated or where antiuicerogenic effect this invention is to provide novel compositions containing is indicated.
  • R&D UNICANCER Annual Report 2016

    R&D UNICANCER Annual Report 2016

    Going further, innovating together R&D UNICANCER Annual Report 2016 Summary Presentation and organisation Regulatory affairs, pharmaco- PAGE 01 vigilance, quality assurance – Ensuring quality and safety 2016 clinical activity in clinical trials. PAGE 08 PAGE 25 Expert groups Epidemiological Strategy and PAGE 16 Medical Economics (ESME) 2016 publications Programme – Harnessing PAGE 21 real-life data in oncology to improve patient care. Clinical operations PAGE 27 PAGE 23 Development Biological Resource and partnerships – Centre (BRC) Optimising collaborations PAGE 24 to foster innovation PAGE 30 Research in the FCCC PAGE 32 Appendices PAGE 33 Contacts, Follow us PAGE 45 GOING FURTHER, INNOVATING TOGETHER R&D ANNUAL REPORT 2016 Presentation and organisation UNICANCER, a major French player in oncology, Acteur majeur de la cancérologie française, groups together 20 French Comprehensive Cancer UNICANCER regroupe les 20 Centres de lutte contre Centers (FCCC). They are private, non-profit health la cancérologie (CLCC), établissements de santé establishments exclusively dedicated to care, research privés à but non lucratif exclusivement dédiés aux and education in cancer. UNICANCER’s R&D soins, à la recherche et à l’enseignement en cancéro- department is the driving force of UNICANCER’s logie. R&D UNICANCER en tant que promoteur research and, as an academic sponsor, it works direc- aca démi que, travaille en direct avec les unités de tly with the research units of the FCCC and other recherche des CLCC et d’autres établissements health establishments (university hospitals, hospitals de santé (CHU, CH, cliniques) en France et à l’inter- and clinics) in France and abroad. The mission of R&D national.
  • WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT

    WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT (51) International Patent Classification: Published: C07D 413/14 (2006.01) A61K 31/553 (2006.01) — with international search report (Art. 21(3)) C07D 403/14 (2006.01) A61P 35/00 (2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/040866 amendments (Rule 48.2(h)) (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,001 06 July 2016 (06.07.2016) 62/454,163 03 February 2017 (03.02.2017) (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office Of Technology Tran s fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: ROSS, Brian, D.; 2410 Foxway, Ann Arbor, MI 48105 (US). VAN DORT, Marcian; 643 Dornoch Dr., Ann Arbor, MI 48103 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
  • Muscarinic Acetylcholine Receptor

    Muscarinic Acetylcholine Receptor

    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
  • Rediscovery of Fexinidazole

    Rediscovery of Fexinidazole

    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2

    Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2

    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.